<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14105">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00333710</url>
  </required_header>
  <id_info>
    <org_study_id>F4120-V</org_study_id>
    <nct_id>NCT00333710</nct_id>
  </id_info>
  <brief_title>Evaluating a Telehealth Treatment for Veterans With Hepatitis C and PTSD</brief_title>
  <official_title>Evaluating a Telehealth Treatment for Veterans With Hepatitis C and PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this proposal is to develop and test the efficacy of two interventions
      (a telehealth and face-to-face intervention) designed to improve quality of life, self-care,
      motivation to engage in healthcare, and psychological distress in patients diagnosed with
      HCV and PTSD. It is hypothesized that
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with comorbid diagnoses of HCV and PTSD may experience increased risk of diminished
      quality of life, given that PTSD is associated with poor self-care and medical
      non-compliance. To date, no systematic efforts to improve quality of life in this high-risk
      population have been documented. The main objective of this proposal is to develop and test
      the feasibility and efficacy of two cognitive-behavioral interventions (a telehealth
      intervention and a face-to-face intervention) designed to improve quality of life,
      self-care, motivation to engage in healthcare, and psychological distress in patients
      diagnosed with HCV and PTSD. A secondary objective is to evaluate the cost effectiveness of
      the interventions. I plan to develop the interventions, pilot test them, and deliver the
      refined treatments to veterans with HCV and PTSD. Participants will be 70 patients from VA
      Boston who meet study criteria. Assessment will occur at pre-treatment, post-treatment, and
      3- and 6-month follow-up. Assessments will measure quality of life, self-care, motivation to
      engage in healthcare, and psychological distress. Analyses will examine study feasibility,
      the effects of the treatment conditions, and the cost effectiveness of the interventions. It
      is hypothesized that the telephone and face-to-face intervention will improve outcomes, as
      compared to treatment as usual, but that the participants will be more satisfied with the
      telephone intervention. In addition, it is predicted that the telephone condition will be
      cost effective as compared to the face-to-face intervention
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Hepatitis C Virus Knowledge Questionnaire</measure>
    <time_frame>pre-treatment, post-treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>This is a 62-item measure which assesses knowledge of the hepatitis C Virus. Range is 0 to 62. Higher scores reflect greater hepatitis C knowledge</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Chronic Disease</condition>
  <condition>Hepatitis C</condition>
  <condition>Stress Disorders, Post-Traumatic</condition>
  <arm_group>
    <arm_group_label>Individual face-to-face contact</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individual face-to-face contact treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Individual telephone contact</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individual telephone contact treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control condition/treatment as usual</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control condition/treatment as usual</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Individual psychotherapy</intervention_name>
    <description>Individual face-to-face contact with educational and goal setting components</description>
    <arm_group_label>Individual face-to-face contact</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telehealth Intervention</intervention_name>
    <description>Individual telephone contact with educational and goal setting components</description>
    <arm_group_label>Individual telephone contact</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of hepatitis C

          -  Clinical diagnosis of posttraumatic stress disorder

          -  Need to have access to a telephone

        Exclusion Criteria:

          -  Life threatening or acute illness

          -  Current alcohol or substance dependence

          -  Currently prescribed interferon treatment

          -  No access to a telephone
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Silberbogen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Jamaica Plain Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Jamaica Plain Campus</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 9, 2014</lastchanged_date>
  <firstreceived_date>June 2, 2006</firstreceived_date>
  <firstreceived_results_date>November 19, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rehabilitation</keyword>
  <keyword>Telecommunication</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Individual Face-to-face Contact</title>
          <description>Individual face-to-face contact treatment
Individual psychotherapy: Individual face-to-face contact with educational and goal setting components</description>
        </group>
        <group group_id="P2">
          <title>Individual Telephone Contact</title>
          <description>Individual telephone contact treatment
Telehealth Intervention: Individual telephone contact with educational and goal setting components</description>
        </group>
        <group group_id="P3">
          <title>Control Condition/Treatment as Usual</title>
          <description>Control condition/treatment as usual</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Individual Face-to-face Contact</title>
          <description>Individual face-to-face contact treatment
Individual psychotherapy: Individual face-to-face contact with educational and goal setting components</description>
        </group>
        <group group_id="B2">
          <title>Individual Telephone Contact</title>
          <description>Individual telephone contact treatment
Telehealth Intervention: Individual telephone contact with educational and goal setting components</description>
        </group>
        <group group_id="B3">
          <title>Control Condition/Treatment as Usual</title>
          <description>Control condition/treatment as usual.
No active treatment</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="16"/>
                <measurement group_id="B4" value="53"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="54.37" spread="4.89"/>
                <measurement group_id="B2" value="52.28" spread="5.19"/>
                <measurement group_id="B3" value="55" spread="6.80"/>
                <measurement group_id="B4" value="53.85" spread="5.64"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="16"/>
                <measurement group_id="B4" value="49"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="16"/>
                <measurement group_id="B4" value="53"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hepatitis C Virus Knowledge Questionnaire</title>
        <description>This is a 62-item measure which assesses knowledge of the hepatitis C Virus. Range is 0 to 62. Higher scores reflect greater hepatitis C knowledge</description>
        <time_frame>pre-treatment, post-treatment</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Individual Face-to-face Contact</title>
            <description>Individual face-to-face contact treatment
Individual psychotherapy: Individual face-to-face contact with educational and goal setting components</description>
          </group>
          <group group_id="O2">
            <title>Individual Telephone Contact</title>
            <description>Individual telephone contact treatment
Telehealth Intervention: Individual telephone contact with educational and goal setting components</description>
          </group>
          <group group_id="O3">
            <title>Control Condition/Treatment as Usual</title>
            <description>Control condition/treatment as usual</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Hepatitis C Virus Knowledge Questionnaire</title>
            <description>This is a 62-item measure which assesses knowledge of the hepatitis C Virus. Range is 0 to 62. Higher scores reflect greater hepatitis C knowledge</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Pre-Treatment</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37.88" spread="10.78"/>
                  <measurement group_id="O2" value="40.50" spread="6.19"/>
                  <measurement group_id="O3" value="35.80" spread="10.05"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post-Treatment</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45.38" spread="7.89"/>
                  <measurement group_id="O2" value="42.36" spread="6.03"/>
                  <measurement group_id="O3" value="34.73" spread="11.09"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During recruitment and when running subjects</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Individual Face-to-face Contact</title>
          <description>Individual face-to-face contact treatment
Individual psychotherapy: Individual face-to-face contact with educational and goal setting components</description>
        </group>
        <group group_id="E2">
          <title>Individual Telephone Contact</title>
          <description>Individual telephone contact treatment
Telehealth Intervention: Individual telephone contact with educational and goal setting components</description>
        </group>
        <group group_id="E3">
          <title>Control Condition/Treatment as Usual</title>
          <description>Control condition/treatment as usual</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size, all male, reliance on self-report measures.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Amy Silberbogen, Ph.D.</name_or_title>
      <organization>VA Boston Healthcare System</organization>
      <phone>857-364-4707</phone>
      <email>amy.silberbogen@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
